Literature DB >> 22863438

Ischemia-modified albumin in patients with hyperthyroidism and hypothyroidism.

Shao-gang Ma1, Liu-xue Yang, Feng Bai, Wei Xu, Bing Hong.   

Abstract

BACKGROUND: The relationship between ischemia-modified albumin (IMA) and thyroid dysfunction remains uncertain. This study aimed to investigate the influence of overt hypothyroidism (Oho), overt hyperthyroidism (Ohe), and their treatments on serum IMA levels.
METHODS: A total of 35 untreated patients with Ohe, 35 untreated patients with Oho, and 35 control subjects were enrolled in the study. C-reactive protein (CRP), homocysteine (Hcy), IMA, and lipid profiles were measured and evaluated before and after treatment.
RESULTS: CRP, Hcy, and IMA levels and lipid profiles were higher in patients with Oho than in euthyroid or Ohe subjects (p<0.05). Basal IMA levels were reduced after treatments in all patients (p<0.05). In Ohe patients, serum IMA levels were positively correlated with free triiodothyronine (r=0.424, p=0.011) and free thyroxine (r=0.567, p<0.001) levels. In Oho patients, serum IMA levels were inversely correlated with free triiodothyronine (r=-0.555, p=0.001) and free thyroxine (r=-0.457, p=0.006) but positively correlated with anti-thyroid peroxidase antibody, C-reactive protein, and homocysteine levels (p<0.05). Linear regression analyses showed that free triiodothyronine was the most important factor affecting serum IMA levels in Ohe (β=0.694, p=0.019) and in Oho (β=-0.512, p=0.025).
CONCLUSIONS: IMA levels are increased in patients with thyroid dysfunction, particularly in overt hypothyroidism. Thyroid dysfunction has a significant impact on the oxidative stress status.
Copyright © 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22863438     DOI: 10.1016/j.ejim.2012.04.011

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  8 in total

1.  Assesment of oxidative status and its association with thyroid autoantibodies in patients with euthyroid autoimmune thyroiditis.

Authors:  Husniye Baser; Ummugulsum Can; Salih Baser; Fatma Humeyra Yerlikaya; Uysaler Aslan; Bahauddin Taha Hidayetoglu
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

2.  Serum ischaemic-modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Varikasuvu Seshadri Reddy; P V L N Srinivasa Rao; M M Suchitra; Renu Garg
Journal:  Endocrine       Date:  2013-10-12       Impact factor: 3.633

3.  Author reply to: serum ischaemic-modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Inan Anaforoğlu; Kerem Ersoy; Ekrem Algün
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

4.  Evaluation of the Relationship Between Ischemia-Modified Albumin Levels and Thyroid Hormone Levels.

Authors:  Mufide Oncel; Aysel Kıyıcı; Serife Onen
Journal:  J Clin Lab Anal       Date:  2014-06-21       Impact factor: 2.352

5.  Ischemia-modified albumin levels in overt and subclinical hypothyroidism.

Authors:  S V Reddy; M M Suchitra; V Pradeep; S Alok; V Suresh; A R Bitla; P V L N Srinivasa Rao
Journal:  J Endocrinol Invest       Date:  2015-04-11       Impact factor: 4.256

6.  Association between plasma homocysteine status and hypothyroidism: a meta-analysis.

Authors:  Yande Zhou; Yufang Chen; Xueqin Cao; Chunfeng Liu; Ying Xie
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  Serum ischemic modified albumin levels might not be a marker of oxidative stress in patients with hypothyroidism.

Authors:  Kerem Ersoy; İnan Anaforoğlu; Ekrem Algün
Journal:  Endocrine       Date:  2012-09-23       Impact factor: 3.633

8.  A meta-analysis of the association of serum ischaemia-modified albumin levels with human hypothyroidism and hyperthyroidism.

Authors:  Varikasuvu Seshadri Reddy; Suman Bukke; Khageshwar Mahato; Vinod Kumar; Netala Vasudeva Reddy; Manne Munikumar; Bramahanapally Vodelu
Journal:  Biosci Rep       Date:  2017-01-27       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.